HomeCompareSCPS vs CL

SCPS vs CL: Dividend Comparison 2026

SCPS yields 500000.00% · CL yields 2.44%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 SCPS wins by $4.663521010693878e+33M in total portfolio value
10 years
SCPS
SCPS
● Live price
500000.00%
Share price
$0.00
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$4.663521010693878e+33M
Annual income
$4,661,686,961,926,996,000,000,000,000,000,000,000,000.00
Full SCPS calculator →
CL
CL
● Live price
2.44%
Share price
$85.23
Annual div
$2.08
5Y div CAGR
28.6%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$41.0K
Annual income
$5,451.69
Full CL calculator →

Portfolio growth — SCPS vs CL

📍 SCPS pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodSCPSCL
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, SCPS + CL cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
SCPS pays
CL pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

SCPS
Annual income on $10K today (after 15% tax)
$42,500,000.00/yr
After 10yr DRIP, annual income (after tax)
$3,962,433,917,637,946,000,000,000,000,000,000,000,000.00/yr
CL
Annual income on $10K today (after 15% tax)
$207.44/yr
After 10yr DRIP, annual income (after tax)
$4,633.94/yr
At 15% tax rate, SCPS beats the other by $3,962,433,917,637,946,000,000,000,000,000,000,000,000.00/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of SCPS + CL for your $10,000?

SCPS: 50%CL: 50%
100% CL50/50100% SCPS
Portfolio after 10yr
$2.331760505346939e+33M
Annual income
$2,330,843,480,963,498,000,000,000,000,000,000,000,000.00/yr
Blended yield
99.96%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on CL right now

SCPS
No analyst data
Altman Z
-250.9
Piotroski
1/9
CL
Analyst Ratings
17
Buy
24
Hold
2
Sell
Consensus: Hold
Price Target
$92.45
+8.5% upside vs current
Range: $85.00 — $100.00
Altman Z
4.5
Piotroski
6/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

SCPS buys
0
CL buys
9
PoliticianChamberTickerTypeAmountDate
John Boozman🏛 Senate$CL▼ Sell$1,001 - $15,0002025-10-09
Ro Khanna🏢 House$CL▼ Sell$1,001 - $15,0002025-10-07
Rick Larsen🏢 House$CL▼ Sell$1,001 - $15,0002025-10-06
Ro Khanna🏢 House$CL▼ Sell$1,001 - $15,0002025-09-29
Julie Johnson🏢 House$CL▼ Sell$1,001 - $15,0002025-09-25
Lisa McClain🏢 House$CL▼ Sell$1,001 - $15,0002025-09-11
Tim Moore🏢 House$CL▼ Sell$1,001 - $15,0002025-09-10
Ro Khanna🏢 House$CL▲ Buy$1,001 - $15,0002025-09-05
Ro Khanna🏢 House$CL▲ Buy$1,001 - $15,0002025-08-26
Lisa McClain🏢 House$CL▲ Buy$1,001 - $15,0002025-08-13
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricSCPSCL
Forward yield500000.00%2.44%
Annual dividend / share$2.00$2.08
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%28.6%
Portfolio after 10y$4.663521010693878e+33M$41.0K
Annual income after 10y$4,661,686,961,926,996,000,000,000,000,000,000,000,000.00$5,451.69
Total dividends collected$4.6634009849658873e+33M$18.1K
Payment frequencyquarterlyquarterly
SectorStockConsumer Staples

Year-by-year: SCPS vs CL ($10,000, DRIP)

YearSCPS PortfolioSCPS Income/yrCL PortfolioCL Income/yrGap
1← crossover$50,010,700$50,000,000.00$11,014$313.84+$50.00MSCPS
2$233,748,371,262$233,694,859,813.08$12,200$415.44+$233748.36MSCPS
3$1,021,074,511,412,696$1,020,824,400,655,446.10$13,607$553.09+$1021074511.40MSCPS
4$4,168,597,328,794,951,700$4,167,504,779,067,739,000.00$15,301$741.41+$4168597328794.94MSCPS
5$15,905,475,114,600,665,000,000$15,901,014,715,458,854,000,000.00$17,374$1,002.00+$15905475114600664.00MSCPS
6$56,718,938,532,531,060,000,000,000$56,701,919,674,158,435,000,000,000.00$19,958$1,367.44+$56718938532531060736.00MSCPS
7$189,031,807,435,623,860,000,000,000,000$188,971,118,171,394,040,000,000,000,000.00$23,243$1,887.87+$1.8903180743562385e+23MSCPS
8$588,799,810,476,518,260,000,000,000,000,000$588,597,546,442,562,100,000,000,000,000,000.00$27,512$2,642.43+$5.8879981047651824e+26MSCPS
9$1,714,064,268,114,722,600,000,000,000,000,000,000$1,713,434,252,317,512,700,000,000,000,000,000,000.00$33,197$3,759.22+$1.7140642681147225e+30MSCPS
10$4,663,521,010,693,878,300,000,000,000,000,000,000,000$4,661,686,961,926,996,000,000,000,000,000,000,000,000.00$40,973$5,451.69+$4.663521010693878e+33MSCPS

SCPS vs CL: Complete Analysis 2026

SCPSStock

Scopus BioPharma Inc., a clinical-stage biopharmaceutical company, focuses on developing transformational therapeutics targeting serious diseases. The company lead development programs are immuno-oncology gene therapy for the treatment of various cancers. It offers Duet Platform, a CpG signal transducer and activator of transcription 3 (STAT3) inhibitors; and MRI-1867, rationally designed, orally available, dual-action, hybrid, and small molecule that is an inverse agonist of the endocannabinoid system/cannabinoid receptor 1, as well as an inhibitor of inducible nitric oxide synthase. Scopus BioPharma Inc. has strategic partnerships with the City of Hope, National Institutes of Health Program, and The Hebrew University of Jerusalem for its lead development and other programs. The company was formerly known as Project18 Inc. and changed its name to Scopus BioPharma Inc. in December 2017. Scopus BioPharma Inc. was incorporated in 2017 and is headquartered in New York, New York.

Full SCPS Calculator →

CLConsumer Staples

Colgate-Palmolive Company, together with its subsidiaries, manufactures and sells consumer products worldwide. The company operates through two segments, Oral, Personal and Home Care; and Pet Nutrition. The Oral, Personal and Home Care segment offers toothpaste, toothbrushes, mouthwash, bar and liquid hand soaps, shower gels, shampoos, conditioners, deodorants and antiperspirants, skin health products, dishwashing detergents, fabric conditioners, household cleaners, and other related items. This segment markets and sells its products under various brands, which include Colgate, Darlie, elmex, hello, meridol, Sorriso, Tom's of Maine, Irish Spring, Palmolive, Protex, Sanex, Softsoap, Lady Speed Stick, Speed Stick, EltaMD, Filorga, PCA SKIN, Ajax, Axion, Fabuloso, Murphy, Suavitel, Soupline, and Cuddly to a range of traditional and eCommerce retailers, wholesalers, and distributors. It also includes pharmaceutical products for dentists and other oral health professionals. The Pet Nutrition segment offers pet nutrition products for everyday nutritional needs under the Hill's Science Diet brand; and a range of therapeutic products to manage disease conditions in dogs and cats under the Hill's Prescription Diet brand. This segment markets and sells its products through pet supply retailers, veterinarians, and eCommerce retailers. Colgate-Palmolive Company was founded in 1806 and is headquartered in New York, New York.

Full CL Calculator →
📬

Get this SCPS vs CL comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

SCPS vs SCHDSCPS vs JEPISCPS vs OSCPS vs KOSCPS vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.